MedTrace Logo

Optimal Allogeneic PRP Concentration for Oocyte In Vitro Maturation in Women With PCOS

NCT07514234 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2026-04-07

No results posted yet for this study

Summary

In vitro maturation is a long-studied technique used to obtain mature oocytes outside the human body. However, this method can increase the risk of ovarian hyperstimulation syndrome (OHSS), particularly in patients with polycystic ovarian syndrome (PCOS). Culture media supplemented with platelet-rich plasma (PRP) has previously shown promise for improving oocyte maturation. This study examined the potential utility of allogeneic PRP supplementation to increase the maturation of germinal vesicle (GV)-stage oocytes collected from PCOS patients who underwent controlled ovarian stimulation. Supplementation with 5% PRP was found to support oocyte maturation under controlled ovarian stimulation. Further investigations are required to refine the use of PRP without controlled ovarian stimulation in clinical IVM protocols that may be beneficial for PCOS patients.

Conditions

  • PCOS (Polycystic Ovary Syndrome)

Interventions

OTHER

PRP plasma rich platelets

An initial pilot experiment tested three different concentrations of PRP supplementation (5%, 25%, and 50%)

Sponsors & Collaborators

  • Gadjah Mada University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
41 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-05
Primary Completion
2023-09-11
Completion
2025-12-09

Countries

  • Indonesia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07514234 on ClinicalTrials.gov